ImmunoAI: Accelerated Antibody Discovery Using Gradient-Boosted Machine Learning with Thermodynamic-Hydrodynamic Descriptors and 3D Geometric Interface Topology
Human metapneumovirus (hMPV) poses serious risks to pediatric, elderly, and immunocompromised populations. Traditional antibody discovery pipelines require 10-12 months, limiting their applicability for rapid outbreak response. This project introduces ImmunoAI, a machine learning framework that accelerates antibody discovery by predicting high-affinity candidates using gradient-boosted models trained on thermodynamic, hydrodynamic, and 3D topological interface descriptors. A dataset of 213 antibody-antigen complexes was curated to extract geometric and physicochemical features, and a LightGBM regressor was trained to predict binding affinity with high precision. The model reduced the antibody candidate search space by 89%, and fine-tuning on 117 SARS-CoV-2 binding pairs further reduced Root Mean Square Error (RMSE) from 1.70 to 0.92. In the absence of an experimental structure for the hMPV A2.2 variant, AlphaFold2 was used to predict its 3D structure. The fine-tuned model identified two optimal antibodies with predicted picomolar affinities targeting key mutation sites (G42V and E96K), making them excellent candidates for experimental testing. In summary, ImmunoAI shortens design cycles and enables faster, structure-informed responses to viral outbreaks.
Code (0)
등록된 구현이 없습니다.
Similar Papers 제목 키워드 기반
Energy-based generative models for monoclonal antibodies
Since the approval of the first antibody drug in 1986, a total of 162 antibodies have been approved for a wide range of therapeutic areas, including cancer, autoimmune, infectious, or cardiovascular diseases. Despite adv…
Drug DiscoveryEpiBench: Can LLMs Understand Epitopes for Antibody Drug Discovery?
Epitopes determine where antibodies bind antigens and shape downstream therapeutic properties such as functional blockade and escape resistance, making epitope understanding central to antibody drug discovery. Although l…
Drug DiscoveryA SARS-CoV-2 Interaction Dataset and VHH Sequence Corpus for Antibody Language Models
Antibodies are crucial proteins produced by the immune system to eliminate harmful foreign substances and have become pivotal therapeutic agents for treating human diseases. To accelerate the discovery of antibody therap…
A model of virus infection with immune responses supports boosting CTL response to balance antibody response
We analyze a within-host model of virus infection with antibody and CD8+ cytotoxic T lymphocyte (CTL) responses proposed by Schwartz et al. (2013). The goal of this work is to gain an overview of the stability of the bio…
Antibody Representation Learning for Drug Discovery
Therapeutic antibody development has become an increasingly popular approach for drug development. To date, antibody therapeutics are largely developed using large scale experimental screens of antibody libraries contain…
Drug DiscoveryLanguage ModellingRepresentation Learning